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Key Points Summary 
- Our objective was to quantify endothelial function (via brachial artery flow-mediated 
dilatation) at sea-level (344m) and high-altitude (3800m) at rest and following both 
maximal exercise and 30-minutes of moderate-intensity cycling exercise with and without 
administration of an 1-adrenergic blockade. 
 
- Brachial endothelial function did not differ between sea-level and high-altitude at rest, nor 
following maximal exercise.  
 
- At sea-level, endothelial function decreased following 30-minutes of moderate-intensity 
exercise, and this decrease was abolished with 1-adrenergic blockade. At high-altitude, 
endothelial function did not decrease immediately post 30-minutes of moderate-intensity 
exercise, and administration of 1-adrenergic blockade resulted in an increase in flow 
mediated dilatation. 
 
- Our data indicates that post-exercise endothelial function is modified at high-altitude (i.e. 
prolonged hypoxemia). The current study helps elucidate the physiological mechanisms 
associated with high-altitude acclimatization, and provides insight into the relationship 
between sympathetic nervous activity and vascular endothelial function.   
Abstract 
We examined the hypotheses that 1) at rest, endothelial function would be impaired at high-altitude 
compared to sea-level, 2) endothelial function would be reduced to a greater extent at sea-level 
compared to high-altitude after maximal exercise, and 3) reductions in endothelial function 
following moderate-intensity exercise at both sea-level and high-altitude are mediated via an 1-
adrenergic pathway. In a double-blinded, counter-balanced, randomized and placebo-controlled 
design, nine healthy participants performed a maximal-exercise test, and two 30-minute sessions 
of semi-recumbent cycling exercise at 50% peak Watt following either placebo or 1-adrenergic 
blockade (prazosin; 0.05mg/kg). These experiments were completed at both sea-level (344m) and 
high-altitude (3800m). Blood pressure (finger photoplethysmography), heart rate 
(electrocardiogram), oxygen saturation (pulse oximetry), and brachial artery blood flow and shear 
rate (ultrasound) were recorded prior to, during, and following exercise. Endothelial function 
assessed by brachial artery flow-mediated dilatation (FMD) was measured prior to, immediately 
following, and 60-minutes post-exercise. Our findings were: 1) at rest, FMD remained unchanged 
between sea-level and high-altitude (placebo P=0.287; prazosin: P=0.110); 2) FMD remained 
unchanged after maximal exercise at sea-level and high-altitude (P=0.244); 3) the 2.90.8% 
(P=0.043) reduction in FMD immediately after moderate-intensity exercise at sea-level was 
abolished via 1-adrenergic blockade. Conversely, at high-altitude, FMD was unaltered following 
moderate-intensity exercise, and administration of 1-adrenergic blockade elevated FMD 
(P=0.032). Our results suggest endothelial function is differentially affected by exercise when 
exposed to hypobaric hypoxia. These findings have implications for understanding the chronic 
impacts of hypoxemia on exercise, and the interactions between the 1-adrenergic pathway and 
endothelial function.  
  
Abbreviations: 
CO, cardiac output 
FMD, flow-mediated dilatation 
HR, heart rate 
MAP, mean arterial pressure 
SNS, sympathetic nervous system 
SpO2, peripheral oxyhemoglobin saturation 
SRAUC, shear rate area under the curve 
SV, stroke volume 
TPR, total peripheral resistance 
  
Introduction 
Flow-mediated dilatation (FMD) is a commonly used, non-invasive measurement of conduit artery 
diameter in response to an imposed change in shear rate; it is widely accepted to be an index of 
endothelial function (Thijssen et al., 2011), and is largely nitric oxide mediated (Green et al., 
2014). It has been demonstrated that immediately after cycling exercise, endothelial function 
measured by brachial (i.e. non-exercising limb) FMD is transiently reduced (Jones et al., 2010, 
Birk et al., 2013, Atkinson et al., 2015, Dawson et al., 2013), and the reduction in FMD is inversely 
related to exercise intensity (Birk et al., 2013). Although the precise mechanisms responsible for 
this acute effect of exercise on FMD remain unclear, several possibilities exist, including:  1) 
elevated oxidative stress (Goel et al., 2007a, Silvestro et al., 2002); 2) altered hemodynamics (i.e. 
shear rate, shear pattern, and blood pressure) (Johnson et al., 2012a, Dawson et al., 2008, Birk et 
al., 2013, Lamping and Dole, 1987, Millgard and Lind, 1998); 3) changes in baseline artery 
diameter post-exercise (Padilla et al., 2007, Atkinson et al., 2013), and; 4) elevations in 
sympathetic nervous system (SNS) activity (Hijmering et al., 2002, Dyson et al., 2006, Atkinson 
et al., 2015). The role of the SNS was recently examined in a study which observed that the 
exercise-mediated reduction in FMD following exercise was abolished after administration of an 
1-adrenergic receptor blockade (Atkinson et al., 2015). Interestingly, the relationship between 
increased SNS activity and post-exercise FMD has not previously been explored under conditions 
where resting SNS activity is chronically elevated, such as in aging, pathology (e.g. obstructive 
sleep apnea, heart failure), or in hypoxia (i.e. normobaric and hypobaric) (Saito et al., 1988, 
Duplain et al., 1999, Xie et al., 2001, Hansen and Sander, 2003). 
Exposure to hypoxia is associated with arterial stiffening, but the effects of hypoxia on 
endothelial function remain unclear (Lewis et al., 2014a, Boos et al., 2012, Rhodes et al., 2011). 
For example, different studies have reported that exposure to simulated high-altitude (i.e. acute 
normobaric hypoxia), results in no change in FMD [~4000m, FIO2 = 0.13; (Iglesias et al., 2015)], 
and decreased FMD [~5000m, FIO2 = 0.11 (Lewis et al., 2014a)]. Upon ascent to high-altitude 
between 3700m-5050m (i.e. hypobaric hypoxia), a decrease in FMD has been observed in most 
(Bakker et al., 2015, Lewis et al., 2014a), but not all studies (Bruno et al., 2015, Bruno et al., 
2016). The disparity within this literature might be due to different methodological approaches 
between investigations. For example, the two studies that reported reductions in FMD involved 
ascent to high-altitude over 7-10 days of trekking for several hours each day (Lewis et al., 2014a, 
Bakker et al., 2015). In contrast, the study that reported no change in FMD involved participants 
ascending rapidly to high-altitude via cable car (Bruno et al., 2015). The methodological difference 
between these studies raises the possibility of a moderating impact of trekking exercise at altitude, 
and total acclimatization time [e.g. 3-10 days of exposure (FMD reduced) vs. 1 day of exposure 
(no change in FMD)] on vascular responses at high-altitude. 
By employing a double-blinded, counter-balanced, randomized and placebo-controlled 
design, the primary purposes of the current study were to investigate: 1) the effects of non-trekking 
(i.e., passive) ascent to high-altitude on endothelial function (via brachial FMD) and shear patterns, 
and 2) the effects of post-exercise related increases in SNS activity on FMD and shear patterns at 
both sea-level and at high-altitude (3800m). We hypothesized that: 1) at rest, FMD would be 
impaired at high-altitude compared to sea-level, 2) FMD would be reduced to a greater extent at 
sea-level compared to high-altitude after maximal exercise, and 3) reductions in endothelial 
function following moderate-intensity exercise at both sea-level and high-altitude are mediated via 
an 1-adrenergic pathway. 
  
Methods and Materials 
Ethical Approval. All experimental procedures and protocols were approved by the clinical 
research ethics board at the University of British Columbia and conformed to the Declaration of 
Helsinki. All participants provided written informed consent prior to participation in this study. 
This study was part of a larger research expedition conducted in October 2015. As such, 
participants took part in a number of studies conducted at the University of British Columbia 
(Kelowna, BC; 344m) and during two weeks at the Barcroft high-altitude research station (White 
Mountain, California, USA; 3800m). However, the a priori, primary research questions addressed 
in the current paper are novel and are exclusively dealt within this study alone – there is no overlap 
between this investigation and others completed on the research expedition.  
 
Participants. Recruited participants (n=11; 3F) were normotensive (systolic blood pressure <140 
and diastolic pressure <90 mmHg) at rest, and completed a medical history questionnaire. Two of 
the recruited participants were excluded from all mean data analysis; one participant due to illness 
(i.e. syncope, light-headedness, nausea) caused by our drug intervention (prazosin), and one 
participant due to illness at high-altitude. The participants (n=9; 2F) included in the data analysis 
were non-smokers, had no previous history of cardiovascular, cerebrovascular, or respiratory 
diseases, were not taking any medications during testing besides oral contraceptives (n=1). All 
participants arrived at the Barcroft high-altitude research facility (elevation = 3800m) on the same 
day, and approximately at the same time (i.e. within one hour). Nine of these participants drove to 
the Barcroft high-altitude research facility after staying overnight in Palm Springs, CA, USA 
(elevation = 146m), while one participant stayed overnight in Bishop, CA, USA (elevation = 
1265m). Maximal exercise testing for this study occurred on day three, while moderate-intensity 
exercise experimentation occurred between days four to seven at high-altitude.  
 Experimental Design.  
This study was conducted in two parts: sea-level and high-altitude investigations. Prior to each 
experiment, all participants abstained from exercise, alcohol, and caffeine for at least 12 hours. 
Additionally, participants were asked to consume a light meal at least two-hours prior to 
experimentation, and to keep their diet consistent between experimentation days. In order to 
determine whether our participants had normal healthy lung function, at sea-level we conducted a 
forced vital capacity (FVC) test to measure lung function, a vital capacity and inspiratory capacity 
maneuver to measure lung volumes, and a single breath carbon monoxide test to quantify diffusing 
capacity on each individual. All testing procedures were conducted in accordance with the 
American Thoracic Society and European Respiratory Society’s joint guidelines (Macintyre et al., 
2005, Miller et al., 2005). For each of these tests, participants sat within a body plethysmography 
box (V6200, Vmax Sensormedics, Yorba Linda, CA, USA) with a rigid upright posture and their 
feet flat on the ground, whilst breathing through a spirometer and bacteriological filter while 
wearing a nose-clip. All pulmonary function measurements were compared against population-
based predictions. 
Exercise testing was then conducted on three separate lab visits at both sea-level and high-
altitude while participants lay in the semi recumbent position. The time of day of the testing 
sessions were kept the same for each participant, with a minimum of 24-hours between testing 
sessions.  
 
Maximal exercise protocols. Prior to the prolonged moderate-intensity exercise testing at sea-level 
and high-altitude, participants were required to conduct a maximal exercise protocol in order to 
obtain peak Watt. In the semi-recumbent position, participants rested during a quiet baseline period 
on the cycle ergometer (Lode Ergometer, Lode, Groningen, Netherlands) for 15-minutes. 
Immediately after the baseline period a brachial artery FMD was performed (Thijssen et al., 2011). 
Exercise began with a two-minute warm-up period (40 watts for females, 60 watts for males), 
followed by staged exercise with workload increased by 20 watts every minute. This maximal 
exercise protocol was terminated when participants either 1) reached volitional exhaustion, or 2) 
cycling cadence could no longer be maintained. Immediately after the maximal exercise protocol 
was completed, another brachial artery FMD was performed. 
 
Moderate-intensity exercise protocol. Following at least 24 hours after the maximal exercise test, 
participants performed two moderate-intensity exercise protocols on two independent days 
separated by at least 24 hours. Upon arrival on each of these testing sessions, participants ingested 
a capsule containing either oral prazosin (1-adrenergic receptor blocker; 0.05 mg kg-1), or Placebo 
(i.e. sugar pill). The order of condition (placebo and prazosin) was counter-balanced and 
randomized at both sea-level and high-altitude. The dosage of prazosin used has been 
demonstrated to provide ~80% 1-adrenergic blockade, and has been used in other studies by our 
research group (Lewis et al., 2014b, Atkinson et al., 2015). Seventy-five-minutes after ingestion, 
participants were instrumented on the semi-recumbent cycle ergometer (see details below in 
section Experimental Measurements). Participants were asked to sit in the semi-recumbent 
position quietly for 15-minutes, and afterwards, a baseline FMD on the left brachial artery was 
conducted. Immediately after the baseline FMD, participants completed 30-minutes of cycle 
exercise at 50% of their peak exercise workload. At sea-level, this workload was 137.0  6.9 Watts, 
while at high-altitude the average workload was 114.3  5.9 Watts. Every five-minutes during 
exercise a one-minute measurement of brachial artery shear rate and blood flow was recorded (total 
of six recordings during the 30 minutes of exercise). After completion of the 30-minutes of 
moderate-intensity exercise, a brachial FMD was conducted immediately, and then following 60-
minutes of post-exercise rest.  
 
Experimental Measurements. 
Cardiovascular measurements. All continuously recorded cardiovascular measurements were 
acquired at 200 Hz using an analog-to-digital converter (Powerlab/16SP ML 880; ADInstruments, 
Colorado Springs, CO, USA) interfaced with a personal computer. Commercially available 
software was used to analyze cardiovascular variables (LabChart V7.1, ADInstruments, Colorado 
Springs, CO, USA). Electrocardiogram electrodes were placed in lead II configuration (Bioamp, 
ML132, ADInstruments, Colorado Springs, CO, USA) to measure heart rate. Beat-by-beat arterial 
pressure, cardiac output, stroke volume, and total peripheral resistance was measured by finger 
photoplethysmography (Finometer Pro, Finapres medical systems, Amsterdam, Netherlands). 
Prior to baseline data collection, the Finometer was calibrated using the return-to-flow function, 
and blood pressure from the Finometer was confirmed with automated brachial blood pressure 
readings (HEM-775CAN, Omron Healthcare, Bannockburn, IL, USA). Mean, systolic, and 
diastolic arterial pressure were quantified from the raw Finometer recordings. 
 
Brachial artery imaging. With the participants left arm extended perpendicular (i.e. 80 degrees) 
from their body while seated on the semi-recumbent cycle ergometer, an inflation/deflation cuff 
was placed on the participants left forearm, and their arm was fixed into position on a table. 
Brachial artery image acquisition was obtained using a 10 MHz multifrequency linear array probe 
attached to a high-resolution ultrasound machine (15L4, Terason t3200, Burlington, MA, USA). 
All brachial artery images were performed by the same experienced ultrasonographer (JT), whom 
has a between day coefficient of variation in FMD of 8.3 ± 2.1% (n=10, unpublished data). 
Following optimal image acquisition, and one-minute of baseline recordings, the forearm was 
occluded by inflating the cuff to 220-250 mmHg for five-minutes. Recordings of diameter and 
velocity continued 30-seconds prior to cuff deflation and continuously for three-minutes thereafter 
(Thijssen et al., 2011).  
 
Data Analysis 
Brachial artery diameter and blood flow analysis. Ultrasound recordings were continuously 
screen captured and saved for offline analysis. Blood flow analysis of the brachial artery was 
performed using automated edge-detection and wall tracking software, which allows for the 
integration of synchronous diameter and velocity measurements to continuously determine flow, 
shear, diameter and velocity at 30-Hz, independent of investigator bias (Woodman et al., 2001). 
Antegrade, retrograde, and mean shear rates were calculated as four times the mean blood velocity, 
divided by vessel diameter. The FMD was calculated as the percent increase in vessel diameter 
from resting baseline diameter, where baseline and peak diameters were automatically detected 
from the continuous data described above.  
 
Statistics 
All statistical analyses were performed using SigmaStat V11 (Systat, Chicago, IL, USA), and were 
reported as mean  SEM. Statistical significance was assumed at P<0.05. When significant F-
ratios were detected, post-hoc comparisons were made using Tukey’s post hoc test for pair-wise 
comparisons. Our study is an extension of a previous study from our laboratory (Atkinson et al., 
2013), which found a ~2% decrease in FMD post 30-minutes of exercise. To detect a 2% decrease 
in post-exercise FMD with a standard deviation of 2%, we calculated that a sample size of 10 
participants was required in order to achieve a statistical power >0.80 with a statistical difference 
of P<0.05. Based on this power calculation, we recruited 11 participants for the sea-level and high-
altitude arms of the study. 
 
Maximal exercise. For the cardiovascular data obtained at sea-level and high-altitude, baseline 
measurements were averaged over one-minute immediately prior to exercise, peak maximal-
exercise data were averaged over the last 30-seconds of the maximal exercise protocol, and post-
maximal exercise data were averaged over one-minute, immediately prior to FMD cuff release 
after maximal exercise was terminated (i.e. approximately four-minutes post-exercise). 
Differences between peak Watt and maximal exercise time at sea-level and high-altitude were 
determined using a paired Student’s t-test. For the cardiovascular data, a two-way repeated 
measures analysis of variance (2RM-ANOVA) was used to detect differences across time 
(baseline, maximal exercise, post-maximal exercise), and conditions (sea-level and high-altitude). 
For the brachial artery data measured during FMD, a 2RM-ANOVA was used to detect differences 
across time (baseline and post-maximal exercise), and conditions (sea-level and high-altitude).  
 
Moderate-intensity exercise. For the cardiovascular data obtained at sea-level and high-altitude, 
baseline measurements were averaged over one-minute immediately prior to exercise. During 
moderate-intensity exercise, cardiovascular data were averaged over 30-seconds at every five-
minute time-point (i.e. time = 5-, 10-, 15-, 20-, 25-, and 30-minutes). Post-exercise cardiovascular 
data were averaged during the one-minute prior to FMD cuff release, immediately after, and 60-
minutes after, moderate-intensity exercise. For the cardiovascular data, a 2RM-ANOVA was used 
to detect differences across time (baseline, exercise [six time-points], and post-exercise [two time-
points]), and conditions (placebo and prazosin), at sea-level and high-altitude, separately. For the 
brachial artery FMD data, a 2RM-ANOVA was used to detect differences across time (baseline, 
post-exercise, 60-minutes post exercise), and conditions (placebo and prazosin), at sea-level and 
high-altitude, separately.  
 
Adjusted flow-mediated dilatation. The effects of time and condition were analyzed within and 
between sea-level and high-altitude for FMD. To determine if our FMD results were different due 
to changes in baseline arterial diameter and/or shear rate area under the curve (SRAUC), we 
included these variables as covariates in a logarithmic-linked generalized linear model, where 
FMD was the dependent variable. This approach has been used to account for any changes in FMD 
that may be related to differences in baseline diameter or shear rate between conditions (i.e. time 
and condition) (Atkinson et al., 2013).  
 
  
Results  
Participants and resting FMD data 
The nine participants included in the sea-level and high-altitude protocol data analysis had a mean 
 SEM age of 26.9  1.8 years, height of 176.3  1.5 cm, and weight of 71.1  2.5 kg. Participants 
had normal pulmonary health with an FVC of 5.5  0.2 L (109.0  3.2% of predicted), forced 
expiratory volume in one-second (FEV1) of 4.3  0.2 L (100.6  2.8% of predicted), FEV1/FVC 
of 78.7  1.0 (no individuals reported under an FEV1/FVC <75), total lung capacity of 6.7  0.3 L 
(101.9  0.3% of predicted), and had a diffusing capacity of the lung for carbon monoxide of 32.1 
 5.7 ml/min/mmHg (94.1  4.7% of predicted). Recruited participants did not demonstrate any 
signs of small nor large airway obstruction characterized by an irregular expiratory flow tracing 
during the FVC maneuver. Additionally, participants were normotensive (systolic blood pressure 
= 130.6  2.5 mmHg, diastolic blood pressure 68.7  1.9 mmHg). 
 No differences were observed in FMD between sea-level and high-altitude during the 
placebo (P=0.287) and prazosin (P=0.110) trials at baseline (see figure 1).  
 
Maximal exercise data 
Figure 2 illustrates the cardiorespiratory data collected during the maximal exercise protocol at 
sea-level and high-altitude. At sea-level, peak Watt and maximal exercise protocol time (min) were 
greater than at high-altitude (275.4  12.4 watts vs. 228.8  11.2 watts, P<0.001; 13.0  0.5 min 
vs. 10.6  0.5 min, P<0.001). Cardiac output and stroke volume were higher at sea-level compared 
to high-altitude (P=0.047 and P=0.032, respectively). In contrast, heart rate at high-altitude was 
elevated compared to sea-level (P=0.038). No differences were observed between sea-level and 
high-altitude for mean arterial pressure or total peripheral resistance at baseline, peak exercise, and 
post-exercise (P=0.130 and P=0.055, respectively). As expected, a main effect was observed for 
SpO2, as it was elevated at sea-level compared to high-altitude (P<0.001).  
 Table 1 illustrates brachial diameter, shear, and FMD data during baseline and post-
maximal exercise at sea-level and high-altitude. Brachial artery diameter was greater at sea-level 
compared to high-altitude across all time-points (P=0.030). At both sea-level and high-altitude, 
brachial artery diameter was reduced post-maximal exercise compared to baseline by 4.8  2.5% 
and 8.7  1.2%, respectively (P=0.004). Mean shear rate increased post-maximal exercise 
compared to baseline at sea-level by 211.2  26.5 1 s-1, and at high-altitude by 101.7  20.9 1 s-1 
(P<0.001). Although a main effect was not present for mean shear rate between sea-level and high-
altitude (P=0.244), an interaction effect was observed post-maximal exercise as mean shear was 
higher at sea-level by 36.1  19.0% compared to high-altitude (P=0.003). Antegrade shear rate 
increased after post-maximal exercise compared to baseline at sea-level by 236.2  20.2 1 s-1, and 
at high-altitude by 163.8  20.3 1 s-1, respectively (both P<0.001); however, similar to mean shear 
rate, altitude had no effect (P=0.833). Retrograde shear rate increased (i.e. became more negative) 
between baseline and post-maximal exercise at sea-level by -25.3  7.8 1 s-1 and at high-altitude 
by 67.4  11.7 1 s-1 (P<0.001). Retrograde shear was also greater (i.e. more negative) at high-
altitude compared to sea-level (P=0.031). 
No differences were found in absolute (mm) or relative changes (FMD) in brachial artery 
diameter between baseline and post-maximal exercise at sea-level or high-altitude (P=0.453 and 
P=0.282, respectively), or between sea-level and high-altitude (P=0.380 and P=0.244, 
respectively). Flow-mediated dilatation SRAUC was greater post-maximal exercise compared to 
baseline (P=0.025), but there was no difference between sea-level and high-altitude (P=0.312). 
When taking into account baseline diameter and SRAUC as covariates, the FMD results remained 
the same as there was no effect of time (P=0.614), altitude (P=0.291), nor was there an interaction 
between these effects (P=0.717) (refer to Figure 3 for individual FMD data at baseline and post-
maximal exercise).  
 
Moderate intensity exercise at sea-level 
Figure 4 (A-F) illustrates the cardiovascular data collected during moderate intensity exercise on 
placebo and prazosin at sea-level. No differences were detected for cardiac output between placebo 
and prazosin during baseline, exercise, and post-exercise (P=0.444). In contrast, prazosin increased 
heart rate (P<0.001), and decreased stroke volume (P=0.026), across all time-points compared to 
placebo. prazosin had no effect on mean arterial pressure (P=0.701), nor total peripheral resistance 
(P=0.492) during baseline, exercise, and post-exercise time-points. Additionally, there was no 
difference in SpO2 between placebo and prazosin trials (P=0.237). 
 Figure 5 (A-C) highlights the brachial antegrade, retrograde, and mean shear rate data 
collected during baseline, exercise, and post-exercise on placebo and prazosin at sea-level. Mean 
and antegrade shear rate were not different between conditions (P=0.567 and P=0.156, 
respectively. Retrograde shear rate was lower (i.e. more negative) during the prazosin trial 
compared to placebo (P=0.037).  
Figure 6 (A-D) illustrates brachial artery velocity, diameter, blood flow and conductance 
data collected during baseline, exercise, and post-exercise on placebo and prazosin at sea-level. 
No differences were found in mean blood flow (P=0.285), forearm vascular conductance 
(P=0.294), artery diameter (P=0.623), nor blood velocity (P=0.400) between the placebo and 
prazosin trials.  
 Figure 7 (A-B) displays FMD data collected at baseline, post-exercise, and 60-minutes post 
exercise on placebo and prazosin at sea-level. No differences in FMD were detected between 
placebo and prazosin (P=0.916), however, there was a time effect during the placebo trial, where 
FMD was reduced immediately post exercise compared to baseline (P=0.043), and 60-minutes 
post-exercise (P<0.001). Additionally, an interaction effect was present between placebo and 
prazosin immediately post-exercise, where FMD was greater during the prazosin trial by 2.9  
1.3% compared to the placebo trial (P=0.039). No differences were found in FMD between placebo 
and prazosin trials during baseline (P=0.762), nor 60-minutes post-exercise (P=0.107). When 
taking into account baseline diameter and SRAUC as covariates, the FMD results remained the 
same as there was still a main effect for time (P=0.016), no effect between conditions (i.e. placebo 
vs prazosin) (P=0.450), and an interaction effect (P=0.026). 
 
Moderate intensity exercise at high-altitude 
Figure 4 (G-L) outlines the cardiovascular data collected during baseline, moderate intensity 
exercise, and post-exercise on placebo and prazosin at high-altitude. No differences were detected 
for cardiac output between placebo and prazosin during baseline, exercise, and post-exercise 
(P=0.825). In contrast, heart rate was elevated (P<0.001), and stroke volume was decreased 
(P=0.006), while on prazosin compared to placebo. prazosin resulted in a lower mean arterial 
pressure (P<0.001), and total peripheral resistance (P<0.001) compared to the placebo trial. 
Interestingly, SpO2 was elevated by 2.5  0.7% (P=0.005) during the prazosin trial compared to 
placebo during the moderate-intensity exercise.  
 Figure 5 (D-F) illustrates brachial shear rate data collected during baseline, moderate-
intensity exercise, and post-exercise on placebo and prazosin at high-altitude. Mean and antegrade 
shear rates were elevated during the prazosin trial compared to the placebo trial across all time-
points (P=0.002 and P<0.001, respectively). However, retrograde shear rate was not different 
between placebo and prazosin (P=0.983).  
Figure 6 (E-H) highlights the brachial artery velocity, diameter, blood flow and 
conductance data collected during baseline, exercise, and post-exercise on placebo and prazosin at 
high-altitude. During the prazosin trial, mean blood flow, conductance, and blood velocity were 
elevated compared to the placebo trial (P=0.004, P=0.008, and P=0.002, respectively). No 
differences were found to brachial artery diameter between placebo and prazosin trials (P=0.516).  
Figure 7 (C-D) illustrates FMD data collected at baseline, post-exercise, and 60-minutes 
post exercise on placebo and prazosin at high-altitude. No differences in FMD were detected 
between time-points (i.e. baseline, post-exercise, and post-60 exercise) (P=0.474), between 
placebo and prazosin (P=0.099). When taking into account baseline diameter and SRAUC as 
covariates, no differences were detected between time-points (P=0.681), nor were any interactions 
present (P= 0.474), which was consistent with our original results. However, we found that there 
was a main effect for condition (i.e. prazosin vs placebo), where FMD was higher with prazosin 
compared to placebo (P=0.032).  
 
  
Discussion 
Using a double-blinded, counter-balanced, randomized and placebo-controlled design, this is the 
first study to examine the role of the SNS system on post-exercise peripheral vascular endothelial 
function at both sea-level (344m) and high-altitude (3800m). Our main findings were 1) at rest, 
brachial artery FMD remained unchanged between sea-level and high-altitude on both placebo and 
prazosin conditions, 2) FMD remained unchanged after maximal exercise at both sea-level and 
high-altitude, and 3) FMD decreased immediately after moderate-intensity exercise at sea-level, 
but not high-altitude. Prazosin abolished the observed post-exercise FMD decrease at sea-level, 
and resulted in an overall increase in FMD at high-altitude compared to placebo when SRAUC 
and baseline diameter were considered as covariates. These data demonstrate that hypobaric 
hypoxia counteracts the effect of moderate intensity exercise on FMD. 
 
Endothelial function between sea-level and high-altitude at rest 
Acclimatization to high-altitude results in several physiological changes, but the effect of high-
altitude on endothelial function remains unclear. At sea-level, recent work has established that 
increases in SNS activity (Hijmering et al., 2002, Dyson et al., 2006, Atkinson et al., 2015), and 
altered hemodynamics (e.g. increased retrograde shear) (Johnson et al., 2012a, Dawson et al., 
2008, Birk et al., 2013, Lamping and Dole, 1987, Millgard and Lind, 1998) can negatively affect 
vascular endothelial function as assessed by FMD. Since both of these physiological changes occur 
during high-altitude exposure, it is logical to hypothesize that endothelial function would be 
reduced at high-altitude, yet we found that there was no change. Comparisons of FMD between 
sea-level and high-altitude have been made previously, but studies have reported contradictory 
results such as reduced FMD (Lewis et al., 2014a, Bakker et al., 2015), or no change in FMD upon 
acclimatization to high-altitude (Bruno et al., 2016, Bruno et al., 2015).  
The major difference between these studies is the mode of transport to altitude – exercise 
versus cable car ascent. We sought to further investigate the effects of non-trekking arrival to high-
altitude on endothelial function, and consistent with the results of Bruno et al. (2015), we found 
no change in endothelial function between sea-level and high-altitude at rest. This finding opposes 
our hypotheses that endothelial function would be impaired at high-altitude due to elevated resting 
SNS activity. Rather, our data indicate that exercise at high-altitude (i.e. trekking) may directly 
effect endothelial function, and we speculate the mechanism(s) for this may be due to increased 
vascular inflammation (Bruno et al., 2016), oxidative stress (Quindry et al., 2015), and reductions 
in nitric oxide bioavailability (Lewis et al., 2014a).  
 
Endothelial function before and after maximal exercise at sea-level and high-altitude 
The degree of observed post-exercise reduction in FMD has been reported to be exercise intensity-
dependent (for review see: Birk et al., 2013); however, few studies have measured FMD after 
maximal exercise in healthy individuals in an inactive limb (i.e, free from exercise) (Thijssen et 
al., 2006, Hwang et al., 2012, McClean et al., 2015). Moreover, no studies to date have reported 
FMD after maximal exercise at high-altitude. Based on previous reports, FMD following maximal 
exercise remains unchanged in the majority of studies (Thijssen et al., 2006, Hwang et al., 2012, 
McClean et al., 2015) but this is not a universal finding (Hwang et al., 2012). Studies 
methodologically similar to ours (Thijssen et al., 2006, Hwang et al., 2012, McClean et al., 2015), 
we demonstrated and further confirm that at sea-level - and for the first time at high-altitude - FMD 
remained unchanged post-maximal exercise at both sea-level and high-altitude. Collectively, these 
findings oppose the idea that post-exercise related decreases in FMD are inversely related to 
exercise intensity (Birk et al., 2013). A likely explanation for this discrepancy is that the exercise 
duration of the maximal exercise test was too short in duration (i.e. exercise volume) to induce a 
reduction in FMD (Johnson et al., 2012b, Dawson et al., 2013). Interestingly, at high-altitude, 
FMD was elevated in a positive direction post-maximal exercise (6.3% to 8.5%); however, this 
observation was not statistically significance. 
 
Endothelial function before and after moderate-intensity exercise at sea-level and high-altitude 
Sea-level: In a different group of subjects, Atkinson et al. (2016) performed a similar investigation 
to the sea-level component of this study and demonstrated that FMD was transiently impaired 
immediately after 30-minutes of moderate-intensity exercise; these changes improved back to pre-
exercise values 60-minutes post moderate-intensity exercise. Atkinson et al. (2016) attributed this 
reduction in FMD to exercise related increases in SNS activity. Congruent with Atkinson et al. 
(2016) and other studies with similar modern methodology to assess FMD (Goel et al., 2007b, 
Dawson et al., 2008, Jones et al., 2010, Johnson et al., 2012a, Birk et al., 2013), we found similar 
results. We acknowledge, however, that such transient reductions in FMD following moderate-
intensity exercise (at least at sea level) should not necessary be interpreted that endothelial 
dysfunction; rather, that FMD that it is influenced by a myriad of factors that may well reflect 
physiological adaptation in other vascular beds, including resistance and conduct arteries. 
 
High-altitude: Although there has been a recent investigation of post-exercise endothelial function 
after moderate-intensity exercise in acute normobaric hypoxia (Katayama et al., 2016), our 
experiment was the first to investigate endothelial function after moderate-intensity exercise at 
high-altitude (i.e. 3800m). In the study by Katayama et al. (2016), endothelial function was not 
different post 30-minutes of moderate-intensity (i.e. 60% VO2 max) exercise between normoxia 
and hypoxia (FIO2 = 0.12-0.13) trials. However, longer exposure to hypoxia (i.e. 4-7 days at high-
altitude) may well yield differential results due to cardiovascular adaptation (Lewis et al., 2014a, 
Boos et al., 2012, Rhodes et al., 2011), and perhaps differential tonic SNS activity (Hansen and 
Sander, 2003). There is evidence suggesting increased SNS activity may be responsible for 
vascular dysfunction directly (Hijmering et al., 2002), or indirectly by increasing retrograde shear 
rate (Thijssen et al., 2014). Due to high-altitude related increases in SNS activity, and based on 
previous reports that endothelial function (via brachial FMD) is reduced upon arrival at high-
altitude in some (Bakker et al., 2015, Lewis et al., 2014a), but not all studies (Bruno et al., 2016), 
we anticipated a reduction in FMD immediately post moderate-intensity exercise at high-altitude. 
Our original hypothesis was not supported as no reduction in FMD was observed post moderate-
intensity exercise, indicating that SNS related blood vessel regulation is different between sea-
level and high-altitude. This latter notion suggests that post-exercise associated elevations in SNS 
activity may have a differential transduction to the peripheral vasculature compared to sea-level.  
 
Effects of 1-adrenergic blockade on endothelial function at sea-level and high-altitude. 
1-adrenergic blockade, results in vasodilatation of the peripheral vasculature by reducing SNS 
transduction directly to smooth muscle cells. At sea-level, prazosin resulted in an increased heart 
rate and decreased stroke volume during exercise. However, the differential heart rate response 
between placebo and prazosin trials did not result in a different blood flow or mean and antegrade 
shear rate response to exercise. Similar to Atkinson et al. (2016), we reported that prazosin 
administration abolished the reduction in endothelial function immediately post 30-minutes of 
moderate-intensity exercise.  
 At rest, SNS blockade has no effect on SpO2 at sea-level (Liu et al., 2007), nor high-altitude 
(Ainslie et al., 2012). During exercise, SpO2 remained the same at sea-level between conditions; 
however, at high-altitude, an unexpected observation was that participants on prazosin had a higher 
SpO2 compared to the placebo trial. This was likely due to increased ventilation during exercise 
on the prazosin trial, perhaps due to baroreflex-chemoreflex interaction, supported by the increased 
heart rate, and reduced stroke volume and mean arterial pressure responses to exercise between 
placebo and prazosin trials. The ventilatory response to changes in arterial blood pressure is related 
to converging baroreceptor and chemoreceptor afferents at the nucleus tractus solitarius (Richter 
and Seller, 1975, Eckberg and Orshan, 1977). A reduction in arterial blood pressure potentiates 
the chemoreflex and results in an increase in ventilation, while an increase in arterial blood 
pressure dampens ventilation (Heistad et al., 1974).  
In contrast to our sea-level data, prazosin resulted in an increased mean and antegrade shear 
rate at high-altitude. These changes were likely facilitated by blockade of SNS vasoconstriction, 
which was likely enhanced at altitude. Increases in antegrade shear rate has been demonstrated to 
have a positive effect on endothelial function (Thijssen et al., 2014). This enhanced antegrade 
shear response at altitude versus sea-level may explain the lack of post exercise FMD impairment, 
and could be in part responsible for the increase in endothelial function observed during the 
prazosin trial at altitude. The increase in FMD observed at high-altitude during the prazosin trial 
compared to the placebo trial suggests that there is indeed some SNS related vascular constraint. 
These data collected at high-altitude indicate that SNS activity is, in part, responsible for the FMD 
response. 
 Methodological considerations. 
The intervention to reduce SNS activity was an 1 specific adrenergic receptor blockade, and the 
dose of administration has been used to establish ~80% blockade in SNS activity, but this was not 
confirmed on an individual basis. An important methodological consideration for the current study 
is that prazosin-  a specific 1-adrenergic receptor blockade was used; therefore, it is possible that 
during prazosin administration there is unopposed upregulation of 2-adrenergic and -adrenergic 
receptor activity (Weisbrod et al., 2001). These net effects likely result in competing 
vasoconstriction and vasodilation effects, respectively. Future studies investigating the role of the 
SNS on endothelial function should consider using both non-selective - and -adrenergic receptor 
blockades, along with a combined - and -adrenergic receptor blockade. Second, we can not 
exclude the possibility that the vascular response to changes in vasodilatory substances is also 
altered (Calbet et al., 2014), and could hence influence our findings. Additionally, we achieved 
adequate power (>0.80) in nearly all of our measurements at sea-level and high-altitude. Although 
our small sample size was smaller than our calculated sample size (n=9 vs n=10), our sea-level 
data replicates previous findings by Atkinson et al. (2015), and we achieved a statistical effect. 
Moreover, additional novelty and statistical power of our study is within the nature of the double-
blinded, counter-balanced, randomized and placebo-controlled design. 
A final consideration is that we did not directly measure SNS activity directly via 
microneurography. Obviously, obtaining muscle SNS measurements in the leg (via peroneal 
nerve) would not be possible during exercise; however, past studies have reported in humans in 
the arm (via radial nerve) (Rea and Wallin, 1989). This approach would not have been feasible 
given our small sample size and the amount of measurements needed in each participant (i.e. twice 
at both sea-level and high-altitude). Nevertheless, both at sea-level and high altitude, we have for 
the first time employed a powerful double-blinded, counter-balanced, randomized and placebo-
controlled study to examine the role of SNS blockade both at rest and during exercise.  
 
Conclusion. 
Our findings illustrate that at sea-level, exercise related increases in SNS activity reduce FMD 
immediately following moderate-intensity exercise, but not at high-altitude. These findings 
indicate that differential governing mechanisms for endothelial function between sea-level and 
high-altitude. Together, our findings have implications for better understanding the chronic 
impacts of hypoxemia and exercise, and the interactions on sympathetic activity and vascular 
function. 
 
  
Acknowledgements: This study was carried out within the framework of the Barcroft high-
altitude research expedition, we thank the research stations staff for their friendly accommodation. 
The authors are grateful to the members of the UBC International Research expedition to the 
Barcroft research facility for invaluable help with organization and implementation of this research 
study. M.M.T., J.C.T., and P.N.A., were responsible for conception and design of the current study. 
All authors contributed to the collection, assembly, analysis, and interpretation of the data, along 
with drafting the article or revising it critically for important intellectual content. All authors 
approved the final version of the manuscript and all persons designated as authors qualify for 
authorship, and all those who qualify for authorship are listed.  
 
Grants: This study was supported by the Natural Sciences and Engineering Research Council of 
Canada (PNA), and the Canadian Foundation for Innovation and a Canada Research Chair (PNA). 
 
Disclosures: The authors have no conflict of interest. 
  
References 
Ainslie PN, Lucas SJ, Fan JL, Thomas KN, Cotter JD, Tzeng YC & Burgess KR (2012). 
Influence of sympathoexcitation at high altitude on cerebrovascular function and ventilatory 
control in humans. J Appl Physiol (1985)113, 1058-1067. 
Atkinson CL, Lewis NC, Carter HH, Thijssen DH, Ainslie PN & Green DJ (2015). Impact of 
sympathetic nervous system activity on post-exercise flow-mediated dilatation in humans. J 
Physiol 593, 5145-5156. 
Atkinson G, Batterham AM, Thijssen DH & Green DJ (2013). A new approach to improve the 
specificity of flow-mediated dilation for indicating endothelial function in cardiovascular 
research. J Hypertens 31, 287-291. 
Bakker E, Engan H, Patrician A, Schagatay E, Karlsen T, Wisloff U & Gaustad SE (2015). 
Acute dietary nitrate supplementation improves arterial endothelial function at high altitude: A 
double-blinded randomized controlled cross over study. Nitric Oxide 50, 58-64. 
Birk GK, Dawson EA, Batterham AM, Atkinson G, Cable T, Thijssen DH & Green DJ (2013). 
Effects of exercise intensity on flow mediated dilation in healthy humans. Int J Sports Med 34, 
409-414. 
Boos CJ, Hodkinson P, Mellor A, Green NP & Woods DR (2012). The effects of acute 
hypobaric hypoxia on arterial stiffness and endothelial function and its relationship to changes in 
pulmonary artery pressure and left ventricular diastolic function. High Alt Med Biol 13, 105-111. 
Bruno RM, Ghiadoni L & Pratali L (2016). Vascular adaptation to extreme conditions: The role 
of hypoxia. Artery Research 14, 15-21. 
Bruno RM, Giardini G, Malacrida S, Catuzzo B, Armenia S, Ghiadoni L, Brustia R, Laveder P, 
Salvi P, Cauchy E & Pratali L (2015). Role of altered vascular reactivity in the pathophysiology 
of acute mountain sickness. Artery Research 12, 29. 
Calbet JA, Boushel R, Robach P, Hellsten Y, Saltin B & Lundby C (2014). Chronic hypoxia 
increases arterial blood pressure and reduces adenosine and ATP induced vasodilatation in 
skeletal muscle in healthy humans. Acta Physiol (Oxf) 211, 574-584. 
Dawson EA, Green DJ, Cable NT & Thijssen DH (2013). Effects of acute exercise on flow-
mediated dilatation in healthy humans. J Appl Physiol (1985) 115, 1589-1598. 
Dawson EA, Whyte GP, Black MA, Jones H, Hopkins N, Oxborough D, Gaze D, Shave RE, 
Wilson M, George KP & Green DJ (2008). Changes in vascular and cardiac function after 
prolonged strenuous exercise in humans. J Appl Physiol (1985) 105, 1562-1568. 
Duplain H, Vollenweider L, Delabays A, Nicod P, Bartsch P & Scherrer U (1999). Augmented 
sympathetic activation during short-term hypoxia and high-altitude exposure in subjects 
susceptible to high-altitude pulmonary edema. Circulation 99, 1713-1718. 
Dyson KS, Shoemaker JK & Hughson RL (2006). Effect of acute sympathetic nervous system 
activation on flow-mediated dilation of brachial artery. Am J Physiol Heart Circ Physiol 290, 
H1446-53. 
Eckberg DL & Orshan CR (1977). Respiratory and baroreceptor reflex interactions in man. J 
Clin Invest 59, 780-785. 
Goel R, Majeed F, Vogel R, Corretti MC, Weir M, Mangano C, White C, Plotnick GD & Miller 
M (2007). Exercise-induced hypertension, endothelial dysfunction, and coronary artery disease 
in a marathon runner. Am J Cardiol 99, 743-744. 
Green DJ, Dawson EA, Groenewoud HM, Jones H & Thijssen DH (2014). Is flow-mediated 
dilation nitric oxide mediated?: A meta-analysis. Hypertension 63, 376-382. 
Hansen J & Sander M (2003). Sympathetic neural overactivity in healthy humans after prolonged 
exposure to hypobaric hypoxia. J Physiol 546, 921-929. 
Heistad DD, Abboud FM, Mark AL & Schmid PG (1974). Interaction of baroreceptor and 
chemoreceptor reflexes. Modulation of the chemoreceptor reflex by changes in baroreceptor 
activity. J Clin Invest 53, 1226-1236. 
Hijmering ML, Stroes ES, Olijhoek J, Hutten BA, Blankestijn PJ & Rabelink TJ (2002). 
Sympathetic activation markedly reduces endothelium-dependent, flow-mediated vasodilation. J 
Am Coll Cardiol 39, 683-688. 
Hwang IC, Kim KH, Choi WS, Kim HJ, Im MS, Kim YJ, Kim SH, Kim MA, Sohn DW & Zo 
JH (2012). Impact of acute exercise on brachial artery flow-mediated dilatation in young healthy 
people. Cardiovasc Ultrasound 10, 39-7120-10-39. 
Iglesias D, Gomez Rosso L, Vainstein N, Merono T, Lezon C & Brites F (2015). Vascular 
reactivity and biomarkers of endothelial function in healthy subjects exposed to acute hypobaric 
hypoxia. Clin Biochem 48, 1059-1063. 
Johnson BD, Mather KJ, Newcomer SC, Mickleborough TD & Wallace JP (2012a). Brachial 
artery flow-mediated dilation following exercise with augmented oscillatory and retrograde shear 
rate. Cardiovasc Ultrasound 10, 34-7120-10-34. 
Johnson BD, Padilla J & Wallace JP (2012b). The exercise dose affects oxidative stress and 
brachial artery flow-mediated dilation in trained men. Eur J Appl Physiol 112, 33-42. 
Jones H, Green DJ, George K & Atkinson G (2010). Intermittent exercise abolishes the diurnal 
variation in endothelial-dependent flow-mediated dilation in humans. Am J Physiol Regul Integr 
Comp Physiol 298, R427-32. 
Katayama K, Yamashita S, Iwamoto E & Ishida K (2016). Flow-mediated dilation in the inactive 
limb following acute hypoxic exercise. Clin Physiol Funct Imaging 36, 60-69. 
Lamping KG & Dole WP (1987). Acute hypertension selectively potentiates constrictor 
responses of large coronary arteries to serotonin by altering endothelial function in vivo. Circ 
Res61, 904-913. 
Lewis NC, Bailey DM, Dumanoir GR, Messinger L, Lucas SJ, Cotter JD, Donnelly J, McEneny 
J, Young IS, Stembridge M, Burgess KR, Basnet AS & Ainslie PN (2014). Conduit artery 
structure and function in lowlanders and native highlanders: relationships with oxidative stress 
and role of sympathoexcitation. J Physiol 592, 1009-24. 
Liu C, Smith TG, Balanos GM, Brooks J, Crosby A, Herigstad M, Dorrington KL & Robbins PA 
(2007). Lack of involvement of the autonomic nervous system in early ventilatory and 
pulmonary vascular acclimatization to hypoxia in humans. J Physiol 579, 215-225. 
Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, Burgos F, 
Casaburi R, Coates A, Enright P, Gustafsson P, Hankinson J, Jensen R, McKay R, Miller MR, 
Navajas D, Pedersen OF, Pellegrino R & Wanger J (2005). Standardisation of the single-breath 
determination of carbon monoxide uptake in the lung. Eur Respir J26, 720-735. 
McClean C, Harris RA, Brown M, Brown JC & Davison GW (2015). Effects of Exercise 
Intensity on Postexercise Endothelial Function and Oxidative Stress. Oxid Med Cell Longev 
2015, 723679. 
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van 
der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, 
Pedersen OF, Pellegrino R, Viegi G, Wanger J & ATS/ERS Task Force (2005). Standardisation 
of spirometry. Eur Respir J26, 319-338. 
Millgard J & Lind L (1998). Acute hypertension impairs endothelium-dependent vasodilation. 
Clin Sci (Lond)94, 601-607. 
Padilla J, Harris RA & Wallace JP (2007). Can the measurement of brachial artery flow-
mediated dilation be applied to the acute exercise model?. Cardiovasc Ultrasound 5, 45. 
Quindry J, Dumke C, Slivka D & Ruby B (2015). Impact of extreme exercise at high altitude on 
oxidative stress in humans. J Physiol [Epub ahead of print]. 
Rea RF & Wallin BG (1989). Sympathetic nerve activity in arm and leg muscles during lower 
body negative pressure in humans. J Appl Physiol (1985)66, 2778-2781. 
Rhodes HL, Chesterman K, Chan CW, Collins P, Kewley E, Pattinson KT, Myers S, Imray CH, 
Wright AD & Birmingham Medical Research Expeditionary Society (2011). Systemic blood 
pressure, arterial stiffness and pulse waveform analysis at altitude. J R Army Med Corps 157, 
110-113. 
Richter DW & Seller H (1975). Baroreceptor effects on medullary respiratory neurones of the 
cat. Brain Res 86, 168-171. 
Saito M, Mano T, Iwase S, Koga K, Abe H & Yamazaki Y (1988). Responses in muscle 
sympathetic activity to acute hypoxia in humans. J Appl Physiol (1985)65, 1548-1552. 
Silvestro A, Scopacasa F, Oliva G, de Cristofaro T, Iuliano L & Brevetti G (2002). Vitamin C 
prevents endothelial dysfunction induced by acute exercise in patients with intermittent 
claudication. Atherosclerosis 165, 277-283. 
Thijssen DH, Atkinson CL, Ono K, Sprung VS, Spence AL, Pugh CJ & Green DJ (2014). 
Sympathetic nervous system activation, arterial shear rate, and flow-mediated dilation. J Appl 
Physiol (1985)116, 1300-1307. 
Thijssen DH, Black MA, Pyke KE, Padilla J, Atkinson G, Harris RA, Parker B, Widlansky ME, 
Tschakovsky ME & Green DJ (2011). Assessment of flow-mediated dilation in humans: a 
methodological and physiological guideline. Am J Physiol Heart Circ Physiol300, H2-12. 
Thijssen DH, de Groot P, Kooijman M, Smits P & Hopman MT (2006). Sympathetic nervous 
system contributes to the age-related impairment of flow-mediated dilation of the superficial 
femoral artery. Am J Physiol Heart Circ Physiol 291, H3122-9. 
Weisbrod CJ, Minson CT, Joyner MJ, Halliwill JR (2001). Effects of regional phentolamine on 
hypoxic vasodilatation in healthy humans. J Physiol 537(Pt 2): 613-21. 
Woodman RJ, Playford DA, Watts GF, Cheetham C, Reed C, Taylor RR, Puddey IB, Beilin LJ, 
Burke V, Mori TA & Green D (2001). Improved analysis of brachial artery ultrasound using a 
novel edge-detection software system. J Appl Physiol (1985)91, 929-937. 
Xie A, Skatrud JB, Puleo DS & Morgan BJ (2001). Exposure to hypoxia produces long-lasting 
sympathetic activation in humans. J Appl Physiol (Bethesda, Md : 1985)91, 1555-62. 
  
Table 1: Brachial artery diameter, shear, and flow-mediated dilatation data during baseline  
and post-maximal exercise at sea-level and high-altitude 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Definition of abbreviations: FMD, flow mediated dilatation; SRAUC, shear rate area under  
the curve. *P<0.05, pre-max data vs post-max data. P<0.05, interaction effect baseline vs post-max 
  
 Sea-Level High-Altitude 
 
Baseline Post-max Baseline Post-max 
Diameter (mm) 4.4  0.2 4.2  0.2* 4.3  0.2 3.9  0.2* 
 Time: P=0.004, Altitude: P=0.030, Interaction: P=0.328 
Mean Shear (1 s-1) 86.4  13.5 297.6  26.2* 111.8  20.1 213.5  27.7* 
 Time: P<0.001, Altitude: P=0.244, Interaction: P=0.003 
Antegrade Shear (1 s-1) 101.7  13.7 337.9  20.5* 144.5  17.3 308.3  24.3* 
 Time: P<0.001, Altitude: P=0.833, Interaction: P=0.012 
Retrograde Shear (1 s-1) -15.2  6.2 -40.5  8.6* -22.1  7.1 -89.6  14.9* 
 Time: P=0.001, Altitude: P=0.031, Interaction: P=0.009 
Change in diameter (mm) 0.23  0.05 0.25  0.05 0.26  0.04 0.32  0.05 
 Time: P=0.453, Altitude: P=0.380, Interaction: P=0.581 
FMD (%) 5.0  1.1 6.2  1.2 6.3  1.3 8.5  1.6 
 Time: P=0.282, Altitude: P=0.244, Interaction: P=0.532 
FMD SRAUC (103 s-1) 23.3  1.9 30.3  2.8* 23.2  2.7 22.6  1.9* 
 Time: P=0.025, Altitude: P=0.312, Interaction: P=0.185 
Table 2: Brachial artery diameter and flow-mediated dilatation data during baseline and post moderate-intensity exercise at 
sea-level and high-altitude 
Definition of abbreviations: FMD, flow mediated dilatation; SRAUC, shear rate area under the curve. *P<0.05, vs pre-exercise data. †P<0.05, 
Post-60 vs Post. P<0.05, Interaction within Post FMD. Bolded Condition: P=0.099, when accounted for baseline diameter and shear rate, 
P=0.032. 
 
  Sea-Level High-Altitude 
  
Pre Post Post-60 Pre Post Post-60 
Diameter Placebo 4.5  0.2 4.8  0.2* 4.4  0.2* 4.2  0.1 4.2  0.1 4.2  0.2 
(mm) Prazosin 4.5  0.2 4.6  0.2 4.6  0.2 4.2  0.2  4.3  0.1 4.2  0.2 
  Time: P=0.015, Condition: P=0.783, Interaction: P=0.008 Time: P=0.496, Condition: P=0.398, Interaction: P=0.501 
Change in diameter  Placebo 0.21  0.03 0.12  0.02 0.30  0.05† 0.26  0.03 0.22  0.04 0.25  0.03 
(mm) Prazosin 0.20  0.04 0.22  0.05 0.22  0.03† 0.29  0.03 0.31  0.05 0.35  0.05 
  Time: P=0.022, Condition: P=0.954, Interaction: P=0.074 Time: P=0.502, Condition: P=0.093, Interaction: P=0.501 
FMD Placebo 4.9  0.7 2.1  0.8* 7.0  1.2† 6.3  0.8 5.3  1.0 5.8  0.6 
(%) Prazosin 4.5  1.0 4.9  1.3 4.0  0.9 6.8  0.8 7.3  1.2 8.5  1.2 
  Time: P=0.013, Condition: P=0.916, Interaction: P=0.033 Time: P=0.474, Condition: P=0.099, Interaction: P=0.455 
FMD SRAUC Placebo 19.8  2.4 37.9  4.5*† 18.3  2.7 26.9  2.8 40.2  5.3*† 25.5  1.7 
(103 s-1) Prazosin 27.4  2.1 39.8  4.7*† 23.7  2.5 30.5  2.5 50.2  3.0*† 37.6  3.2 
  Time: P<0.001, Condition: P=0.060, Interaction: P=0.448 Time: P<0.001, Condition:  P=0.005, Interaction: P=0.287 
Figure Legends 
Figure 1. FMD data collected during baseline on placebo and prazosin at sea-level and high-
altitude. White bars represent sea-level data  SEM, and black bars represent high-altitude data  
SEM in 9 participants. Definitions of abbreviations: FMD, flow-mediated dilatation. These 
findings illustrate that there were no differences in resting FMD between sea-level and high-
altitude after passive ascent to 3800m.  
 
Figure 2. Cardiovascular data during baseline, maximal exercise, and post-maximal exercise 
at sea-level and high-altitude. Open circles () represent sea-level data  SEM, and closed circles 
() high-altitude data  SEM in 9 participants. *P<0.05, for interaction effects. Statistics for main 
effects and interactions are displayed on the top right of each figure panel. Definitions of 
abbreviations: BL, baseline; Max-Ex, maximal exercise; Post-Max, post-maximal exercise; SpO2, 
percent oxygen saturation of hemoglobin; SV, stroke volume, HR, heart rate; CO, cardiac output; 
MAP, mean arterial pressure; TPR, total peripheral resistance. Collectively, these findings reveal 
that SV, HR, CO, and SpO2 were all elevated at sea-level compared to high-altitude during a 
maximal exercise test.  
 
Figure 3. Individual FMD data collected at baseline and post-maximal exercise at sea-level 
and high-altitude. Mean data (n=9) is represented by the gray line plot. Definitions of 
abbreviations: BL, baseline; Post-Max, post-maximal exercise; FMD, flow-mediated dilatation. 
These data reveal that we found no change in FMD post maximal exercise at sea-level and high-
altitude.  
 
Figure 4. Cardiovascular data during baseline, moderate-intensity exercise, and post-
exercise on placebo and prazosin at sea-level and high-altitude. Open circles () represent 
placebo data  SEM, and closed circles () represent prazosin data  SEM in 9 participants. 
*P<0.05, for interaction effects. Statistics for main effects and interactions are displayed on the 
top right of each figure panel. Definitions of abbreviations: BL, baseline; Post, immediately post-
exercise; Post 60, 60-minutes post-exercise; SpO2, percent oxygen saturation of hemoglobin; SV, 
stroke volume, HR, heart rate; CO, cardiac output; MAP, mean arterial pressure; TPR, total 
peripheral resistance. These findings demonstrate that at sea-level, SV was elevated, while HR 
was reduced on placebo compared to prazosin during 30-minutes of moderate-intensity exercise. 
At high-altitude, SPO2 and HR were lower, while MAP and HR were higher on placebo compared 
to prazosin during 30-minutes of moderate-intensity exercise.  
 
Figure 5. Brachial artery shear rate data during baseline, moderate-intensity exercise, and 
post-exercise on placebo and prazosin at sea-level and high-altitude. Open circles () represent 
placebo data  SEM, and closed circles () represent prazosin data  SEM in 9 participants. 
*P<0.05, for interaction effects. Statistics for main effects and interactions are displayed on the 
top right of each figure panel. Definitions of abbreviations: BL, baseline; Post, immediately post-
exercise; Post 60, 60-minutes post-exercise. These data reveal that retrograde shear rate was 
greater after prazosin administration at sea-level, while at high-altitude, mean and antegrade shear 
rate were greater after prazosin administration compared to placebo during 30-minutes of 
moderate-intensity exercise.  
 
Figure 6. Brachial artery velocity, diameter, blood flow and conductance data collected 
during baseline, moderate-intensity exercise, and post-exercise on placebo and prazosin at 
sea-level and high-altitude. Open circles () represent placebo data  SEM, and closed circles 
() represent prazosin data  SEM in 9 participants. *P<0.05, for interaction effects. Statistics for 
main effects and interactions are displayed on the top right of each figure panel. Definitions of 
abbreviations: BL, baseline; Post, immediately post-exercise; Post 60, 60-minutes post-exercise. 
These findings illustrate that there were no differences found in brachial artery velocity, diameter, 
blood flow and conductance at sea-level between placebo and prazosin trials, however, at high-
altitude, we found brachial artery velocity, blood flow and conductance were reduced while 
participants were on placebo compared to prazosin during the 30-minute moderate-intensity 
exercise test.  
 
Figure 7. Individual FMD data collected during baseline and post-exercise on placebo and 
prazosin at sea-level and high-altitude. Mean data (n=9) is represented by the gray line plot. 
*P<0.05, represents time effect, where FMD Post-EX was lower compared to baseline, and Post-
60 (for more details, see results section). Definitions of abbreviations: Post, immediately post-
exercise; Post 60, 60-minutes post-exercise; FMD, flow-mediated dilatation. Collectively, these 
findings reveal that at sea-level, FMD was reduced immediately after 30-minutes of moderate-
intensity exercise while on placebo, and the reduction in FMD was abolished after administration 
of prazosin. At high-altitude, there was no observed reduction in FMD immediately after 30-
minutes of moderate-intensity exercise after administration of placebo or prazosin. Additionally, 
after taking into account for changes in brachial baseline diameter and shear rate between placebo 
and prazosin trials, FMD was elevated after administration of prazosin compared to placebo at 
high-altitude.  
